PL EN


Preferences help
enabled [disable] Abstract
Number of results
2005 | 5 | 4 | 212-216
Article title

Obraz kliniczny i przebieg schizofrenii oraz zasady leczenia w zależności od współwystępującego używania substancji psychoaktywnych

Content
Title variants
EN
Clinical picture and course of schizophrenia as well as the principles of treatment depending on concomitant use of psychoactive substances
Languages of publication
EN PL
Abstracts
EN
The article presents some issues of the impact of the use of various psychoactive substances on the clinical picture and course of treatment of schizophrenic patients. The use of psychoactive substances by people with schizophrenic disorders creates some problems with a proper diagnosis, because it may modify the clinical picture (it exacerbates psychotic symptoms) and course of the disease. Significant for modification of the clinical picture and course of the disease is the use – by the same people – of several psychoactive substances, such as cannabinoids, amphetamine or cocaine, sometimes combined with almezokorcohol. In such cases it is very difficult to determine the effects of each substance on psychopathological symptoms, course of the disease and interaction with antipsychotic drugs. The patients with concomitant use of psychoactive substances and schizophrenia exhibit also more depressive symptoms, higher risk of suicidal attempts, more prevalent positive than negative symptoms, besides schizophrenia of paranoid type is diagnosed more frequently. Treatment of patients, who exhibit schizophrenic disorders and use psychoactive substances may create more health hazards related to an enhanced number of drug-induced adverse symptoms (e.g. tardive dyskinesias) or of symptoms intensity. The course of the disease is disadvantageous, the disease recurs more often, the drugs are often found to be ineffective, therefore it often becomes necessary to use higher doses of antipsychotic drugs.
PL
W pracy omówiono zagadnienia wpływu stosowania różnych substancji psychoaktywnych (SPA) na obraz kliniczny i przebieg leczenia osób chorych na schizofrenię. Używanie SPA przez osoby z zaburzeniami schizofrenicznymi stwarza problemy z ustaleniem prawidłowej diagnozy, gdyż może modyfikować obraz kliniczny (zaostrza objawy psychotyczne) i przebieg choroby. Istotne znaczenie dla modyfikacji obrazu klinicznego i przebiegu choroby ma używanie przez te same osoby kilku substancji psychoaktywnych, takich jak kanabinole, amfetamina czy kokaina, czasem w połączeniu z alkoholem. W takich przypadkach bardzo trudne jest określanie efektu działania każdej substancji na objawy psychopatologiczne, przebieg choroby i interakcję z lekami przeciwpsychotycznymi. W obrazie klinicznym u osób chorujących na schizofrenię, które jednocześnie używają SPA stwierdza się większe nasilenie objawów depresyjnych, zwiększone ryzyko podejmowania prób samobójczych, częstsze występowanie objawów pozytywnych niż negatywnych, częściej niż zazwyczaj rozpoznaje się schizofrenię typu paranoidalnego. Leczenie osób z zaburzeniami schizofrenicznymi używających SPA może stwarzać więcej zagrożeń zdrowotnych związanych z wystąpieniem większej liczby niepożądanych objawów polekowych (np. późnych dyskinez) lub większym nasileniem tych objawów. Przebieg choroby jest niekorzystny, występuje zwiększenie liczby nawrotów choroby, częściej stwierdza się niedostateczne efekty działania leków i z tego względu w wielu przypadkach zachodzi konieczność zastosowania zwiększonych dawek leków przeciwpsychotycznych.
Discipline
Publisher

Year
Volume
5
Issue
4
Pages
212-216
Physical description
Contributors
  • Klinika Zaburzeń Afektywnych i Psychiatrii Młodzieżowej Uniwersytetu Medycznego w Łodzi. Kierownik: prof. dr hab. n. med. Jolanta Rabe-Jabłońska
References
  • 1. Buckley P.F.: Substance abuse in schizophrenia: A review. J. Clin. Psychiatry 1998; 59 (supl. 3): 26-30.
  • 2. De Quardo J.R., Carpenter C.F., Tandon R.: Patterns of substance abuse in schizophrenia: Nature and significance. J. Psych. Res. 1994; 28: 267-275.
  • 3. Khalsa H.K., Shaner A., Anglin M.D., Wang J.: Prevalence of substance abuse in a psychiatric evaluation unit. Drug Alcohol Dependence 1991; 28: 215-223.
  • 4. Mueser K.T., Yarnold PR., Bellack A.S.: Diagnostic and demographic correlates of substance abuse in schizophrenia and major affective disorder. Acta Psychiatr. Scan. 1992; 85: 48-55.
  • 5. Shaner A., Khalsa E., Roberts L. i wsp.: Unrecognized cocaine use among schizophrenic patients. Am. J. Psychiatry 1993; 150: 758-762.
  • 6. Regier D.A., Farmer M.E., Rae D.S. i wsp.: Comorbidity of mental disorders with alcohol and other drug abuse: Results from the Epidemiological Catchment Area (ECA) Study. JAMA 1990; 264: 2511-2518.
  • 7. Cuffel B.J.: Prevalence estimates of substance abuse in schizophrenia and their correlates. J. Nerv. Ment. Dis. 1992; 180: 589-596.
  • 8. LeDue PA., Mittelman G.: Schizophrenia and psychostimulant abuse: A review and reanalysis of clinical evidence. Psychopharmacology 1995; 121: 407- 427.
  • 9. Haywood T.W., Kravitz H.M., Grossman L.S. i wsp.: Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am. J. Psychiatry 1995; 152: 856-861.
  • 10. Kane J.M.: Compliance issues in autpatient treatment. J. Clin. Psychopharmacol. 1985; 5: 225-275.
  • 11. Owen R.R., Fischer E.P, Booth B.M., Cuffel B.J.: Medication noncompliance and substance abuse among patients with schizophrenia. Psych. Serv. 1996; 47: 853-858.
  • 12. Van Putten T.: Why do schizophrenic patients refuse to take their drugs? Arch. Gen. Psychiatry 1978; 31: 61-72.
  • 13. Bartels S.J., Teague G.B., Drake R.E. i wsp.: Substance abuse in schizophrenia: Service utilization and cost. J. Nerv. Mental Dis. 1993; 181: 227-232.
  • 14. Salloum I.M., Moss H.B., Daley D.C.: Substance abuse and schizophrenia: Impediments to optimal care. Am. J. Drug Alcohol Abuse 1991; 17: 321-336.
  • 15. Batel P: Addiction and schizophrenia. Eur. Psychiatry 2000; 15: 115-122.
  • 16. Buckley P., Thompson P., Way L., Meltzer H.Y.: Substance abuse among patients with treatment-resistant schizophrenia: Characteristics and implications for clozapine therapy. Am. J. Psychiatry 1995; 151: 385-389.
  • 17. Gottesman I.I., Groome C.S.: HIV/AIDS risks as a consequence of schizophrenia. Schizophr. Bull. 1997: 23: 675-684.
  • 18. Carey M.P, Carey K.B., Kalichman S.C.: Risk for human immunodeficiency virus (HIV) infection among persons with severe mental illnesses. Clin. Psychol. Rev. 1997; 17: 271-291.
  • 19. Cuffel B.J., Heithoff K., Lawson W.: Correlates of patterns of substance abuse among patients with schizophrenia. Hosp. Community Psychiatry 1993; 44: 247-251.
  • 20. Eronen M., Tiihonen J., Hakda P.: Schizophrenia and homicidal behaviour Schizophr. Bull. 1996; 22: 83-89.
  • 21. Tardiff K, Marzul P.M., Leon A.C. i wsp.: Violence by patients admitted to a private psychiatric hospital. Am. J. Psychiatry 1997; 154: 88-93.
  • 22. Hambrecht M., Hafner I.I.: Substance abuse and the onset of schizophrenia. Biol. Psychiatry 1996; 40: 155-163.
  • 23. Dixon L., Haas G., Weiden P. i wsp.: Acute effects of drug abuse in schizophrenic patients: Clinical observations and patients’ self-reports. Schizophr. Bull. 1990; 16: 69-79.
  • 24. Rosenthal K.N., Hellerstein D.J., Miner C.K: Integrated services for treatment of schizophrenic substance abusers: demographics, symptoms, and substance abuse patterns. Psychiatr. Q 1992; 63: 3-26.
  • 25. Brady K. , Anton R., Ballenger J.C. i wsp.: Cocaine abuse among schizophrenic patients. Am. J. Psychiatry 1990; 147: 1164-1167.
  • 26. Lysaker P., Bel! M., Beam-Goulet J., Milstein R.: Relationship of positive and negative symptoms to cocaine abuse in schizophrenia. J. Nerv. Ment. Dis. 1994; 182; 109-112.
  • 27. Galanter M., Casteneda R., Ferman J.: Substance abuse among general psychiatric patients: place of presentation, diagnosis and treatment. Am. J. Drug Alcohol Abuse 1988; 14: 211-235.
  • 28. Miller N.S., Mahler J.C., Belkin B.M., Gold M.S.: Psychiatric diagnosis in alcohol and drug dependence. Ann. Clin. Psychiatry 1991; 3: 79-89.
  • 29. Sokolski K.N., Cummings J.L., Abrans B.I. i wsp.: Effects of substance abuse on hallucination rates and treatment responses in chronic psychiatric patients. J. Clin. Psychiatry 1994; 55: 380- 387.
  • 30. Schuckit M.A.: The history of psychotic symptoms in alcoholics. J. Clin. Psychiatry 1982; 43: 53-57.
  • 31. Mueser K.T., Bellack A.S., Blanchard J.J.: Comorbidity of schizophrenia and substance abuse: Implications for treatment. J. Cons. Clin. Psychology 1992; 60: 845-856.
  • 32. Shiloh R., Nutt D., Weizman A.: Atlas of Psychiatric Pharmacotherapy. Taylor & Francis Group, London 2002.
  • 33. Heizer J.E., Pryzbeck T.R: The cooccurence of alcoholism with other psychiatric disorders in the general population and its impact on treatment. J. Stud. Alcohol 1988; 49:219-224.
  • 34. Chambers A.R., Krystal J.H., Self D.W: A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol. Psychiatry 2001; 50: 71-83.
  • 35. Lieberman J.A., Kinon B.J., Loebel A.D.: Dopaminergic mechanisms in idiopathic and drug-induced psychosis. Schizophr. Bull. 1990; 16: 97-100.
  • 36. Sinha R., Catapano D., O’Malley S.: Stress induced craving and stress response in cocaine dependent individuals. Psychopharmacology 1999; 142: 343-351.
  • 37. Steward J.: Pathways to relapse: The neurobiology of drug and stress-induced relapse to drug taking. J. Psychiatry Neurosci. 2000; 25: 125-136.
  • 38. Van Ammers E.C., Sellman J.D., Mulder K.T.: Temperament and substance abuse in schizophrenia: Is there a relationship? J. Nerv. Ment. Dis. 1997; 185: 283-288.
  • 39. Soyka M.: Addiction and schizophrenia. Nosological, clinical and therapeutic questions. Substance dependence and schizophrenia. Fortschr. Neurol. Psychiatr. 1994; 62: 186-196.
  • 40. Krausz M., Mesz R., Heasen C., Gross J.: Psychopathology in patients with schizophrenia and substance abuse: a comparative clinical study. Psychopathology 1996; 29: 95-103.
  • 41. Allebeck P., Varla A., Kristijansson E., Wistedt B.: The study of substance abuse in schizophrenia. Risk factors for suicide among patients with schizophrenia. Acta Psychiatr. Scand. 1987; 76: 414-419.
  • 42. Drake R.E., Wallach M.A.: Substance abuse among the chronically mentally ill. Hosp. Comm. Psychiatry 1989; 40: 1041-1046.
  • 43. Heila H., Isometsa E.T., Henrikson M.M. i wsp.: Suicide and schizophrenia: a nationwide psychological autopsy study on age- and sex-specific clinical characteristics of 92 suicide victims with schizophrenia. Am. J. Psychiatry 1997; 154: 1235-1242.
  • 44. Swartz M.S., Swanson J.W., Hiday VA. i wsp.: Violence and severe mental illness: the effects of substance abuse and nonadherence to medication. Am. J. Psychiatry 1998; 155: 226-231.
  • 45. Miller N.S., Eriksen A., Owley T.: Psychosis and schizophrenia in alcohol and drug dependence. Psych. Ann. 1994; 24: 418-423.
  • 46. Dyck E .: Flashback: psychiatric experimentation with LSD in historical perspective. Can. J. Psychiatry 2005; 50: 381-388.
  • 47. Selzer J.A., Lieberman J.A.: Schizophrenia and substance abuse. Psychiatr. Clin. North Am. 1993; 16: 401-412.
  • 48. Zisook S., Heaton R., Moranville J. i wsp: Past substance abuse and clinical course of schizophrenia. Am. J. Psychiatry 1992; 149: 552-553.
  • 49. Kirchner J.E., Owen R.R., Nordquist C., Fischer E.P.: Diagnosis and management of substance use disorders among inpatients with schizophrenia. Psych. Serv. 1998; 49: 82-85.
  • 50. Carey K.B.: Substance use reduction in the context of outpatient psychiatric treatment: A collaborative, motivational, harm reduction approach. Comm. Men. Health J. 1996; 32: 291-306.
  • 51. Kovasznay B., Fleischer J., Tanenberg-Karant M.: Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizoph. Bull. 1997; 23: 195-201.
  • 52. D’Mello D.A., Boltz M.K., Msibi B.: Relationship between concurrent substance abuse in psychiatric patients and neuroleptic dosage. Am. J. Drug Alcohol Abuse 1995; 21: 257-265.
  • 53. Bowers M.B. Jr., Mazure M., Nelson J.C., Jetlow P.I.: Psychogenic drug use and neuroleptic response. Schizophr. Bull. 1990; 16: 81-85.
  • 54. Baigent M., Holme G., Harrier R.J.: Self reports of the interaction between substance abuse and schizophrenia. Aust. N. Z. J. Psychiatry 1995; 29: 69-74.
  • 55. Conley R.R., Kelly D.L., Gale EA.: Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. Schizophr. Res. 1998; 33: 95-101.
  • 56. Potvin S., Stip E., Roy J.Y.: Schizophrenia and addiction: An evaluation of the self-medication hypothesis. Encephale 2003; 29: 193-203.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-8203e4d7-9f37-456e-bb64-b31b5bb371ad
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.